Cervical Cancer Prevention (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (06/16/2017)

Overview

Added text to note that based on solid evidence, screening with the Papanicolaou test and screening with the human papillomavirus (HPV) DNA test reduces cervical cancer incidence; these screening test are covered in the Cervical Cancer Screening summary.

Description of Evidence

Revised text to state that all forms of the HPV vaccine are currently recommended by the Centers for Disease Control and Prevention (CDC) in the United States as a two-dose schedule at least 6 months apart for adolescents younger than 15 years; the current CDC recommendation for older individuals is to receive the original three-dose series. Also added text to state that a recent international study compared a two-dose schedule with a three-dose schedule in adolescents younger than 15 years who received the 9-valent HPV vaccine; the antibody response was noninferior in the two-dose schedule, supporting the current recommendation that two doses are sufficient for this age group (cited Iversen et al. as reference 28).

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Description of Evidence

Next section >
About This PDQ Summary